Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

MiNK Therapeutics Q3 2026 Results: Net Loss of $2.55M, Loss Narrows

MiNK Therapeutics reported a net loss of $8.4 million for the first nine months of 2026, an improvement from the $9.9 million loss in the prior year period. The company recorded its first pre-commercial product revenue of $200,000 and maintained a cash balance of $7.5 million as of September 30, 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.20.0
Net income-2.6-2.9
EPS (diluted, $ a share)$-0.50$-0.65

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: INKT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

MiNK Therapeutics, Inc.: key numbers

Share price
$9.35Close, Nov 16
Market cap
$48M
Shares outstanding
5.13MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from MiNK Therapeutics, Inc.

All →
9:50 AM ET 8-K
Financial Results

MiNK Therapeutics Financial Results

MiNK Therapeutics reported third quarter 2026 financial results, highlighting its first pre-commercial product revenue from agenT-797 via an international named-patient access program. The company also noted its selection for an ARPA-H program with up to $87 million in team-wide funding and the advancement of its randomized Phase 2 ARDS trial.

Term
Q3 2026

“We now have a randomized trial running in critical illness, multiple clinical programs enrolling and a path toward pivotal development. This quarter, physicians outside our trials began requesting agenT-797 for their patients, bringing our first pre-commercial revenue. The same unmodified iNKT cells, from the same donor, that drove a 77% disease control rate in PD-1-refractory gastroesophageal cancer are now in a placebo-controlled trial in ARDS, where nearly four in ten patients die and no effective approved drug changes that outcome. Our focus now is delivering the randomized readout designed to show what these cells can do for these patients.”

Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics
2:37 PM ET Form 4
Insider Selling

MiNK Therapeutics CEO Jennifer Buell Sells $73.3K of Stock

Jennifer Buell, CEO, sold 6,938 shares of MiNK Therapeutics, Inc. at $10.56 a share, worth $73.3K in total on Oct 12, 2026. Shares held after the trade: 74,195 (-8.6%).

Value
$73.3K
Shares
6,938
Price
$10.56
Role
CEO
Holding change
-8.6%
Trade date
Oct 12, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.